DeepMed Research

UNIVERSITY OF SOUTHERN CALIFORNIA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1880-01-01

Employees: 10K

Market Cap: -

Website: http://startusc.com

Clinical Trials

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Gallbladder Carcinoma
Stage III Gallbladder Cancer AJCC V7
Stage IIIB Gallbladder Cancer AJCC v7
Gallbladder Adenocarcinoma, Biliary Type
Stage IIIA Hepatocellular Carcinoma AJCC v7
Stage IIIB Hepatocellular Carcinoma AJCC v7
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type
Recurrent Hepatocellular Carcinoma
Recurrent Pancreatic Carcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v7

Interventions: Biological: Durvalumab
Drug: Guadecitabine

First Posted Date: 2017-08-22

Last Posted Date: 2025-03-03

Lead Sponsor: University of Southern California

Target Recruit Count: 55

Registration Number: NCT03257761

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Topical Treatment and Prevalence of P. Acnes

Phase 2

Completed

Conditions: Surgical Site Infection

Interventions: Drug: Clindamycin 1% Gel
Drug: Benzoyl peroxide 5% gel
Drug: BenzaClin 5%-1% Topical Gel

First Posted Date: 2017-08-22

Last Posted Date: 2019-11-13

Lead Sponsor: University of Southern California

Target Recruit Count: 12

Registration Number: NCT03257202

Locations: 🇺🇸
Keck School of Medicine of the University of Southern California, Los Angeles, California, United States

Intra-articular Adipose Tissue Injections for Osteoarthritis

Not Applicable

Conditions: Osteoarthritis, Knee

Interventions: Biological: Autologous adipose tissue injection
Drug: Hyaluronic Acid

First Posted Date: 2017-08-08

Last Posted Date: 2019-10-03

Lead Sponsor: University of Southern California

Target Recruit Count: 54

Registration Number: NCT03242707

Locations: 🇺🇸
Keck Medicine of USC, Los Angeles, California, United States

Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors

Not Applicable

Withdrawn

Conditions: Stage II Bladder Urothelial Carcinoma
Transitional Cell Carcinoma
Infiltrating Bladder Urothelial Carcinoma

Interventions: Procedure: Biopsy
Device: High-Intensity Focused Ultrasound Ablation
Other: Laboratory Biomarker Analysis
Procedure: Radical Cystectomy
Device: Ultrasonography

First Posted Date: 2017-08-03

Last Posted Date: 2018-01-02

Lead Sponsor: University of Southern California

Registration Number: NCT03238664

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

Not Applicable

Active, not recruiting

Conditions: Health Status Unknown
Elevated PSA

Interventions: Procedure: Biopsy of Prostate
Other: Laboratory Biomarker Analysis
Diagnostic Test: Magnetic Resonance Imaging
Diagnostic Test: MRI Ultrasound Fusion Guided Biopsy

First Posted Date: 2017-07-31

Last Posted Date: 2024-04-26

Lead Sponsor: University of Southern California

Target Recruit Count: 288

Registration Number: NCT03234556

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Henry Ford Hospital Vattikuti Urology Institute, Detroit, Michigan, United States

and more 1 locations

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

Recruiting

Conditions: Healthy Subject
Hematopoietic and Lymphoid Cell Neoplasm
Hematologic and Lymphocytic Disorder
Immune System Disorder
Malignant Neoplasm

Interventions: Procedure: Biospecimen Collection
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration

First Posted Date: 2017-07-05

Last Posted Date: 2024-05-24

Lead Sponsor: University of Southern California

Target Recruit Count: 500

Registration Number: NCT03207854

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

TExT-MED + FANS Full Trial

Phase 2

Completed

Conditions: Diabetes

Interventions: Behavioral: TExT-MED
Behavioral: FANS

First Posted Date: 2017-06-07

Last Posted Date: 2021-08-06

Lead Sponsor: University of Southern California

Target Recruit Count: 166

Registration Number: NCT03178773

Locations: 🇺🇸
LAC+USC Medicine Center Emergency Department, Los Angeles, California, United States

Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer

Not Applicable

Completed

Conditions: Breast Carcinoma

Interventions: Other: Contrast Agent
Procedure: Digital Tomosynthesis Mammography
Procedure: Dual-Energy Contrast-Enhanced Digital Spectral Mammography

First Posted Date: 2017-06-06

Last Posted Date: 2021-11-18

Lead Sponsor: University of Southern California

Target Recruit Count: 43

Registration Number: NCT03176979

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Sedentary Behavior and Health Outcomes Study

Not Applicable

Completed

Conditions: Physical Activity
Sedentary Lifestyle
Metabolic Disturbance
Pediatric Obesity

Interventions: Behavioral: Walking breaks
Behavioral: Sitting only

First Posted Date: 2017-05-15

Last Posted Date: 2020-11-13

Lead Sponsor: University of Southern California

Target Recruit Count: 35

Registration Number: NCT03153930

Locations: 🇺🇸
University of Southern California Keck School of Medicine, Los Angeles, California, United States

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Previously Treated Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Decitabine
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Recombinant EphB4-HSA Fusion Protein

First Posted Date: 2017-05-10

Last Posted Date: 2019-04-18

Lead Sponsor: University of Southern California

Target Recruit Count: 7

Registration Number: NCT03146871

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy